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Introduction 31 
Ischaemic heart disease persists as the leading global cause of death.[1] Myocardial infarction 32 
(MI) accounts for a large proportion of death due to cardiovascular disease. Between 2007 and 33 
2016, age-sex standardised mortality for MI in Scotland has fallen by 42.5% from 129 to 74 34 
per 100,000 population[2] – a trend also apparent in other countries.[3] [4] Despite 35 
improvements in survival, considerable disparities exist according to sex in terms of delivery 36 
of guideline-recommended treatments and outcomes following MI suggesting women may be 37 
disadvantaged.[5]  38 
Use of high-sensitivity troponin assays with sex-specific thresholds increases the detection of 39 
MI in women.[6] However, women are less likely to undergo percutaneous coronary 40 
revascularisation (PCI) and are more often subject to underutilisation of evidence-based 41 
secondary preventative pharmacotherapy.[5] [7] [8]  Differences in adoption of invasive 42 
management may, in part, be explained by a perception held by clinicians and patients that 43 
outcomes are worse for women receiving PCI, as well as differences in symptoms and baseline 44 
risk profile which may impact clinical decision-making.[9] Adverse events post-MI, including 45 
cardiogenic shock, heart failure and death, remain more common in women than in men, most 46 
notably in those with ST-elevation myocardial infarction (STEMI).[10] [11] Whether sex 47 
remains an independent predictor of adverse events despite adjustments for the higher risk-48 
profile of women, notably age, is less clear. 49 
We hypothesised that sex-related differences in demographics and comorbidity underpin 50 
disparities in management and outcomes of women and men hospitalised with MI or angina. 51 
We investigated this hypothesis by analysis of a contemporary secondary care electronic 52 
registry (e-Registry) using electronic patient records (EPRs) for patients admitted to a complex 53 
regional healthcare network.[12]  54 




Seven acute hospitals in the National Health Service (NHS) in Glasgow and the West of 57 
Scotland provide a complex healthcare system serving a population of approximately 1.2 58 
million. The Golden Jubilee National Hospital is a regional cardiothoracic centre that provides 59 
invasive cardiology services for this population. EPRs were implemented across all secondary 60 
care clinical and administration systems in NHS Greater Glasgow and Clyde (GGC) and the 61 
Golden Jubilee National Hospital by June 2012 enabling capture of key components of 62 
hospital care. These EPRs have been combined into an e-Registry for quality improvement and 63 
research.[12] 64 
The Information Services Division is part of NHS National Services Scotland and holds a 65 
range of health-related administrative data, including information relating to medicines 66 
dispensed in the community within its Prescribing Information System (PIS) database, 67 
morbidity collected from all hospital admissions in the Scottish Morbidity Record 01 (SMR01) 68 
database and all deaths registered by National Records of Scotland (NRS). Once data were 69 
extracted, identifiers were removed and replaced with a pseudonymous identifier. The research 70 
team accessed these pseudonymised datasets within a Safe Haven analytical platform.[13] 71 
Ethics and governance 72 
The project was supported by the National Advisory Committee for Coronary Heart Disease 73 
on behalf of the Scottish Government. The Joint Working Project received ethical approval 74 
from the NHS GGC Local Privacy Advisory Committee and was approved by hospital 75 
management and the Caldicott Guardian for clinical governance in each health board. 76 
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Design and methodology 77 
Data were extracted from EPRs for all admissions (01/10/13-30/06/16) with an International 78 
Statistical Classification of Diseases (ICD-10) diagnosis of angina (I200-I209), MI (I210-79 
I229), other ischaemic heart disease (I240-I249), or heart failure (I50) to ensure complete 80 
capture of events. Data were deposited within an existing repository for electronic health data 81 
and linked to electronic referrals for cardiovascular procedures performed in the invasive 82 
centre. An executable system was developed to identify, link and classify these records into 83 
episodes of care as detailed in a previous project.[12] Patients with a final diagnosis of MI or 84 
angina were isolated and linked to PIS prescribing data, SMR01 data for comorbidities and 85 
mortality data from NRS. This linked dataset was analysed to look at patient characteristics, 86 
invasive cardiovascular procedures, service delivery metrics, drug treatment and mortality. The 87 
pre-specified primary outcomes were 30 day and 1 year all-cause mortality (from date of 88 
admission). The receipt of cardiac interventions and medical therapy at discharge, 6 months 89 
and 1 year post-discharge were the pre-specified secondary outcomes. 90 
Statistical analysis 91 
Baseline characteristics were described using means with standard deviations, total numbers 92 
with percentages, or medians with interquartile ranges. Where all patients were analysed, this 93 
included unspecified MI. Comparisons between men and women were made using appropriate 94 
statistical tests (t-test/Mann-Whitney/chi-squared/Fisher’s exact). Deprivation status was 95 
identified based on home postcode and measured using quintiles of the Scottish Index of 96 
Multiple Deprivation (SIMD) 2012 measure.[14] Quintile 1 represents the highest level of 97 
deprivation with quintile 5 representing the least deprived. The top 20% most deprived data 98 
zones in Scotland are in quintile 1, and the distribution of Glasgow’s data zones is 49%, 19%, 99 
13%, 10.5%, 8.5% (Q1-Q5).[15] A Charlson comorbidity score was derived using standard 100 
procedures and ICD-10 codes included the hospital admission records.[16] Pre-admission 101 
medical therapy and medical therapy at discharge were defined as fulfilment of prescription 102 
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within 90 days pre-admission and post-discharge, respectively. Medical therapy at 6 months 103 
and at 1 year were defined as fulfilment of prescription at 6 months or 1 year post-discharge 104 
+/- 45 days.  105 
To analyse the relationship between sex and medical treatment, three analyses using mixed 106 
effects logistic models were performed for each drug and drug combination: (1) for patients 107 
alive at discharge, fulfilling a prescription claim within 90 days of discharge, (2) for patients 108 
discharged with treatment and alive at 6 months post-discharge, fulfilling a prescription claim 109 
at 6 months post-discharge, (3) for patients discharged with treatment and alive at 1 year post-110 
discharge, fulfilling a prescription claim at 1 year post-discharge. Analyses were adjusted for 111 
age, SIMD, use of the respective drug within 90 days pre-admission, comorbidities and PCI. 112 
Furthermore, we adjusted for clustering at the discharge hospital level. When analysing the 113 
association of sex with use of drug combinations, pre-admission drug use was not adjusted for. 114 
Multivariable logistic regression was used to evaluate the association of sex and baseline 115 
factors with invasive management. Cox proportional hazards regression was used to evaluate 116 
the association of sex with all-cause mortality. Kaplan-Meier survival curves were generated 117 
for all-cause death and sex differences were assessed using a log rank test. Analyses were 118 
conducted using SAS Enterprise Guide (v5.1).  119 
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Results 120 
Baseline characteristics  121 
There were 7878 patients admitted with MI or angina between 1 October 2013 and 30 June 122 
2016, including 3161 (40.1%) women (Table 1). Diagnosis of STEMI was made in 2042 123 
(25.9%) patients, non-ST-elevation myocardial infarction (NSTEMI) in 3957 (50.2%) patients, 124 
hospitalised angina in 1425 (18.1%) patients, and in 454 (5.8%) patients the MI type was 125 
unspecified. Women were older than men (69.7 years vs 64.0 years, p<0.0001) and were 126 
relatively more deprived (75.7% vs 72.5% in SIMD Q1-3, p=0.0016). Diagnosis of STEMI 127 
was less common in women than men (20.3% vs 29.7%, p<0.0001), but women had a higher 128 
proportion of NSTEMI (51.7% vs 49.2%, p <0.001) and hospitalised angina (21.4% vs 15.9%, 129 
p<0.0001). Comorbidity differed according to sex both in terms of higher Charlson scores and 130 
an increased proportion of individual comorbid diseases in women, who more frequently had 131 
hypertension, atrial fibrillation, renal failure, respiratory disease, cerebrovascular disease, 132 
stroke, heart failure, dementia and depression. Compared to men, women were more often 133 
treated with statins (46.9% vs 43.2%, p=0.0013), beta-blockers (34.9% vs 30.5%, p<0.0001) 134 
and anticoagulants or antiplatelets (48.5% vs 42.1%, p<0.0001) pre-admission. 135 
Invasive management 136 
Approximately 16% fewer women than men underwent coronary angiography (52.1% vs 137 
68.2%, p<0.001) and PCI (30.3% vs 46.5%, p<0.001) (Table 1). Amongst those who had a 138 
coronary angiogram, women received PCI 10% less frequently than men (58.1% vs 68.1%, 139 
p<0.001). The difference in median duration of hospital stay was 1 day (5 days for women vs 4 140 
days for men, p<0.001). In patients with STEMI, 6.2% fewer women than men were 141 
transferred for immediate invasive management (63.6% vs 69.8%, p=0.0117) and the median 142 
door-to-balloon time was longer for women (23mins vs 21mins, p<0.0001) (Supplementary 143 
Table 1a). We also examined the effect of age on door-to-balloon time; in those above 65 144 
years, the median time was 3 minutes longer for women than for men (24mins vs 21mins, 145 
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p<0.0001), whereas no difference existed in those under 65 years (21mins vs 21mins, 146 
p=0.2287).  147 
The sex differences in demographic characteristics were similar for patients with STEMI and 148 
NSTEMI (Supplementary Tables 1a and 1b). In patients hospitalised with angina, there were 149 
fewer differences although women were older and less frequently received invasive 150 
management (Supplementary Table 1c). 151 
Predictors of coronary angiography and PCI 152 
After adjusting for differences in age, deprivation and comorbidities, sex was an independent 153 
predictor of both coronary angiography and PCI in all patients (Table 2). For patients with 154 
STEMI, men were more likely to receive coronary angiography (adjusted OR:1.44 CI:1.05-155 
1.97) and PCI (adjusted OR:1.62 CI:1.28-2.05). The same was true for patients with NSTEMI 156 
(coronary angiography adjusted OR:1.48 CI:1.26-1.75, PCI adjusted OR:1.52 CI:1.32-1.76).  157 
Several baseline characteristics were found to be independently associated with lower use of 158 
coronary angiography and PCI in patients with MI including older age, prior MI in STEMI, 159 
and heart failure in NSTEMI (Figures 1a and 1b). There were few major sex differences within 160 
subgroups; most notably, in those with NSTEMI and renal failure men were less likely than 161 
women to receive PCI, and in those with NSTEMI and dementia women were less likely than 162 
men to receive coronary angiography and PCI. 163 
Medical therapy post-MI 164 
Women were less frequently treated with antiplatelets than men (with no greater treatment 165 
with anticoagulants), with a difference at 1 year of 2.8% (p=0.0368) (Figure 2). At 1 year, 166 
women were also less often prescribed statins (3.8% difference, p=0.0048) and ACE 167 
inhibitors or ARBs (4.3% difference, p=0.003). A similar pattern was seen in the NSTEMI 168 
group (Supplementary Figure 1b). In this group, women were also less frequently treated 169 
with beta-blockers at 1 year. Drug therapy was similar for men and women at 1 year in the 170 
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STEMI and hospitalised angina groups, other than anticoagulants, with which fewer women 171 
than men were treated (Supplementary Figures 1a and 1c). In patients with STEMI or 172 
hospitalised angina, sex was not an independent predictor of treatment with anticoagulants or 173 
antiplatelets, statins, ACE inhibitors or ARBs or beta-blockers at 1 year (Supplementary 174 
Table 2). Conversely, in NSTEMI men were 20-32% more likely than women to be treated 175 
with statins, ACE inhibitors or ARBs, or beta-blockers at 1 year. 176 
Death 177 
Case-fatality at 30 days was 4.9% in all patients, 6.9% in STEMI patients and 2.9% in 178 
NSTEMI patients (Table 3). Case-fatality at 1 year was 10.9% in all patients, 10% in STEMI 179 
and NSTEMI patients and 5.1% in patients hospitalised for angina. Survival was worse for 180 
women than for men, driven by marked differences in outcomes in STEMI (Figure 3); in this 181 
group, 6.3% more women than men had died by 1 year (14.3% vs 8.0%, p<0.0001). However, 182 
after adjustment for baseline demographics, comorbidities and PCI, the association between 183 
sex and mortality after STEMI was not significant and male sex emerged as an independent 184 
predictor of death in patients with NSTEMI (1 year HR:1.38 CI:1.12-1.69) (Table 3). A 185 
subgroup analysis of those patients treated with PCI showed similar results.  186 
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Discussion 187 
In this study of 7878 patients with hospitalised with MI or angina from 2013-2016 we found 188 
that women had a higher crude rate of death but, after accounting for baseline risk factors, men 189 
were more likely to die following NSTEMI, with no difference for patients with STEMI or 190 
hospitalised angina. After taking account of baseline risk factors, there remain sex disparities 191 
for patients with MI related to treatment times, invasive management and use of secondary 192 
prevention therapies. Our findings highlight the need for renewed focus on achieving health 193 
equity for women and men through prioritisation of guideline-directed management. 194 
Our analysis serves evidence of the persistently high crude mortality event rate in women, 195 
particularly with STEMI. We found that death from any cause was 2.6% more common 196 
amongst women than men at 1 year, driven predominantly by deaths in the STEMI population 197 
for whom the crude difference was in excess of 6%. The survival curves for men and women 198 
with STEMI separate almost immediately, and this is reflected in the 3.6% mortality difference 199 
as early as 30 days. In this study, the crude differences were explained by the older age of 200 
women compared to men, greater burden of comorbidity, higher relative degree of deprivation 201 
and reduced access to coronary angiography and PCI.  202 
We have included a comprehensive indicator of social deprivation which measures deprivation 203 
across seven weighted domains. In our study, women were more often from deprived 204 
socioeconomic groups. Socioeconomic deprivation is strongly linked with poorer outcomes in 205 
MI and in women the effect is more prominent.[17] In Scotland, rates of coronary 206 
revascularisation have increased across all deprivation categories over the past 10 years with 207 
the exception of the least deprived.[2]  208 
Important sex differences in cardiovascular risk factors are evident; diabetes and hypertension 209 
are more common in women (particularly younger women), and they may increase risk more 210 
in women than men.[18] There are a number of other risk factors specific to women, including 211 
hypertensive disorders of pregnancy and pregnancy-related diabetes mellitus, which are 212 
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associated with a higher later cardiovascular risk.[19] We evaluated additional important 213 
comorbidities, notably dementia and depression. Although we must interpret the results with 214 
caution due to small numbers of patients identified with each condition, the presence of 215 
dementia was associated with a lower likelihood of coronary angiography. Dementia likely 216 
serves as a disincentive for clinicians and the families of affected patients to adopt invasive 217 
management. It’s rising prevalence and emergence as a leading cause of death in women in 218 
several countries will increase the magnitude of this disparity.[20] [21] Large trials to 219 
investigate the appropriate treatment strategy for older patients with MI, including those with 220 
dementia, are underway.[22] [23] 221 
We found that an invasive strategy was used less often in the management of women with MI 222 
than it was for men, and this mirrors existing literature.[5] [7] [24] [25] Women were less 223 
likely to undergo coronary angiography and PCI. Our analyses suggest that this factor may, in 224 
part, explain why crude survival is worse for women than it is for men.  There are several 225 
reasons why this discrepancy may exist. There were notable differences in route of admission 226 
to hospital, with fewer women than men taken directly to the catheterisation laboratory 227 
irrespective of MI type. This will incur delays to revascularisation and may reduce the 228 
likelihood of coronary angiography altogether. Differences in admission route may be 229 
explained by greater diagnostic uncertainty amongst women, who report non-specific or 230 
atypical symptoms more often than men.[26] Data on the time between symptom onset and 231 
first contact with medical services would highlight delays in presentation, when the benefits of 232 
emergent coronary revascularisation are less certain. Finally, emergency care decisions 233 
regarding coronary angiography and PCI in women may be influenced by smaller coronary 234 
anatomy, more technically challenging vascular access (the excess door-to-balloon time seen 235 
in older women in this study may also reflect this), and greater risk of procedure-related 236 
complications and post-procedural mortality.[25] Although bleeding complications remain 237 
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more prevalent in women despite accounting for age, comorbidity and medication use, major 238 
adverse cardiac events are largely explained by baseline factors such as these.[25] [27] 239 
A further important finding of our study is that male sex was independently associated with a 240 
higher risk of death in patients with NSTEMI. This association has been recognised previously 241 
and highlights the importance of evaluating subtypes of MI separately.[28] [29] The reason for 242 
this is likely multifactorial. One possible explanation is that women have less obstructive 243 
coronary artery disease than men and, in post-menopausal women, more efficient vascular 244 
tissue repair.[30] Differences in provision of primary preventative medical therapy may also 245 
contribute towards the findings. Finally, we lack data on cigarette smoking. In MI, smoking is 246 
not only more prevalent in men than in women[5] [24], but is also thought to be associated 247 
with different pathologic mechanisms – predominantly plaque rupture and acute thrombosis in 248 
men, and plaque erosion with superimposed thrombosis in women.[31] 249 
Our study has a number of limitations. In addition to those that are inherent to the retrospective 250 
design, we were unable to include several important prognostic variables, including 251 
haematological and biochemical bloods tests, biomarkers, haemodynamics, left ventricular 252 
systolic function, coronary anatomy and extent of disease. We lack information regarding rates 253 
of prior PCI, subsequent coronary artery bypass grafting and symptom-burden after the event. 254 
However, women are less likely than men to undergo coronary artery bypass grafting and, 255 
even in the absence of adjusting for this, the crude association between female sex and death 256 
was removed. A further confounder is lack of data on sex of the treating physician; female 257 
patients with MI treated by male physicians are less likely to survive than if treated by female 258 
physicians, and greater male physician-experience in treating female patients is linked to better 259 
outcomes.[32]  260 
Conclusion  261 
Survival at 30 days and 1 year following STEMI is worse for women than for men. However, 262 
this is explained by relative differences in baseline characteristics such as older age, greater 263 
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deprivation, more prevalent comorbidity and lower rates of coronary angiography and PCI. 264 
Differences in the use of evidence-based drug therapy following MI also exist, with women at 265 
a disadvantage. Amongst patients with NSTEMI, male sex is an independent predictor of 266 
mortality. Efforts to address these sex disparities should be directed towards better 267 
understanding the differences in baseline risk and care pathways in order to highlight areas that 268 
would benefit from target, sex-specific intervention. 269 
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